Express Scripts (ESRX) Looks to Battle EpiPen with New Program; Leerink Affirms at 'Market Perform' (MYL)
Tweet Send to a Friend
Leerink affirms Express Scripts (Nasdaq: ESRX) with a Market Perform rating and $80 price target after the company announced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
